Trial Profile
Evaluation of the long-term efficacy and safety of zolpidem-MR [modified release] 12.5 mg compared to placebo, when both are administered over a long-term period 'as needed', in patients with chronic primary insomnia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 16 Jul 2009
Price :
$35
*
At a glance
- Drugs Zolpidem (Primary)
- Indications Insomnia
- Focus Pharmacodynamics; Therapeutic Use
- Acronyms ZOLONG
- Sponsors Sanofi
- 08 Apr 2009 Actual end date (Jan 2006) added as reported by ClinicalTrials.gov.
- 29 Jun 2007 Results have been reported.
- 15 Feb 2007 New trial record.